Skip to content
Screener

R&D at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
$5.19M-35.0%
XER
Xeris Biopharma Holdings, Inc.XERS
$10.67M+32.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$4.49M+30.7%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$36.09M-4.7%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$14.75M-10.8%
PVL
Palvella TherapeuticsPVLA
$9.33M+129%

Other financials

Income statement

See full
Revenue-
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%
EPS (diluted)-$0.16-14.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.19B+152%
Enterprise value$1.18B+143%

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Savara’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344585
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Operating expenses:
Research and development$21,951$20,751$45,349$39,910
General and administrative18,98610,65534,55419,901
Depreciation and amortization28345263
Total operating expenses40,96531,44079,95559,874
Loss from operations(40,965)(31,440)(79,955)(59,874)
Other income, net:
Interest income, net8299211,9102,420

Cover / Front Matter

FAQ

What is Savara's R&D?
Savara (SVRA) reported R&D of $21.95M in Q2 2026.
How has Savara's R&D changed year-over-year?
Savara's R&D increased by 5.8% year-over-year, from $20.75M to $21.95M.
What is the long-term trend for Savara's R&D?
Over 4 years (2021 to 2025), Savara's R&D has grown at a 29.4% compound annual growth rate (CAGR), from $28.99M to $81.4M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Savara's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude